Evaluating the utility of <i>ZNF331</i> promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance).

Epigenetics · 2024 · PMC11085945 · PMID 38716804

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Furthermore, while patients whose tumours demonstrated ZNF331 promoter hypermethylation and received IFL adjuvant therapy had a numerically shorter DFS and OS, this did not reach statistical significance.

also in 111,027 other papers

a numerical trendno p-value reported

While they did not observe a statistically significant reduction in OS by Kaplan-Meier analysis, there was a numerical trend towards reduced survival in patients whose tumours demonstrated ZNF331 methylation.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Evaluating the utility of &lt;i&gt;ZNF331&lt;/i&gt; promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance).

The sentences

Evaluating the utility of <i>ZNF331</i> promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance).